阿达木单抗注射液联合风湿骨痛胶囊治疗肾虚督寒型强直性脊柱炎患者的效果观察  

The effect of adalimumab injection combined with Fengshi Gutong capsule in the treatment of ankylosing spondylitis with kidney deficiency and governor cold

作　　者：申悦 纵何香 王健雄 储依然 赵旭 马伶俐 徐胜前[1] Shen Yue;Zong Hexiang;Wang Jianxiong;Chu Yiran;Zhao Xu;Ma Lingli;Xu Shengqian(Department of Rheumatology and Immunology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)

机构地区：[1]安徽医科大学第一附属医院风湿免疫科,合肥230022

出　　处：《中国医药》2024年第7期1066-1070,共5页China Medicine

基　　金：吴阶平医学基金会临床科研专项资助基金(320.6750.2020-03-4)。

摘　　要：目的观察阿达木单抗注射液联合风湿骨痛胶囊治疗肾虚督寒型强直性脊柱炎(AS)患者的临床效果。方法选取2021年5月至2023年4月于安徽医科大学第一附属医院风湿免疫科确诊的AS患者77例。所有患者随机分为对照组(39例)和观察组(38例)。对照组给予阿达木单抗联合艾瑞昔布治疗,观察组给予阿达木单抗联合风湿骨痛胶囊治疗。比较2组患者的治疗前资料,治疗前后实验室检查结果、疾病活动指标、临床达标率以及安全性指标。结果2组患者治疗前各指标比较差异均无统计学意义(均P>0.05)。治疗6个月后,对照组临床医师整体评估(PGA)评分、BathAS疾病活动性指数(BASDAI)、AS疾病活动性积分(ASDAScrp)、红细胞沉降率(ESR)和C反应蛋白(CRP)均低于治疗前;观察组BASDAI、ESR和CRP均低于治疗前,临床达标率高于治疗前,差异均有统计学意义(均P<0.05)。治疗12个月后,对照组指地距、PGA评分、BASDAI、ASDAScrp、ESR和CRP均低于治疗前,胸廓扩张度和临床达标率均高于治疗前;观察组指地距、PGA评分、BASDAI、ASDAScrp、ESR和CRP均低于治疗前,腰椎活动度和临床达标率均高于治疗前,差异均有统计学意义(均P<0.05)。治疗12个月后,观察组胃肠道不适发生率低于对照组[0(0/22)比16.7%(4/24)],差异有统计学意义(χ^(2)=4.016,P=0.045)。结论肾虚督寒型AS患者采用阿达木单抗注射液联合风湿骨痛胶囊治疗,与阿达木单抗注射液联合艾瑞昔布治疗效果相当,可为AS的治疗提供新的选择。Objective To observe the clinical effect of adalimumab injection combined with Fengshi Gutong capsule in the treatment of ankylosing spondylitis(AS)of kidney deficiency and governor cold.Methods A total of 77 AS patients diagnosed in the Department of Rheumatology and Immunology,the First Affiliated Hospital of Anhui Medical University from May 2021 to April 2023 were selected.All patients were randomly divided into control group(39 cases)and observation group(38 cases).The control group was treated with adalimumab combined with imrecoxib,and the observation group was treated with adalimumab combined with Fengshi Gutong capsule.The data before treatment,laboratory examination results,disease activity index,clinical compliance rate before and after treatment and safety indicators were compared between the two groups.Results There were no statistically significant differences in all indicators between the two groups before treatment(all P>0.05).After 6 months of treatment,the physician global assessment(PGA)score,BathAS disease activity index(BASDAI),AS disease activity score(ASDAScrp),erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP)in the control group were lower than those before treatment,BASDAI,ESR and CRP in the observation group were lower than those before treatment,and the clinical compliance rate was higher than that before treatment(all P<0.05).After 12 months of treatment,the finger-ground distance,PGA score,BASDAI,ASDAScrp,ESR and CRP in the control group were lower than those before treatment,and the chest expansion and clinical compliance rate were higher than those before treatment,the finger-ground distance,PGA score,BASDAI,ASDAScrp,ESR and CRP in the observation group were lower than those before treatment,and the lumbar activity and clinical standard rate were higher than those before treatment,and the differences were statistically significant(all P<0.05).After 12 months of treatment,the incidence of gastrointestinal discomfort in the observation group was lower than that in the con

关 键 词：强直性脊柱炎 阿达木单抗 风湿骨痛胶囊 临床疗效 

分 类 号：R593.23[医药卫生—内科学]